Literature DB >> 1442617

A comparison of hospital and community-acquired infective endocarditis.

S C Chen1, D E Dwyer, T C Sorrell.   

Abstract

The epidemiology, clinical features, microbiology and outcome of 30 episodes of nosocomial endocarditis occurring over a 13-year period were reviewed and compared with 148 cases of community-acquired endocarditis. Twenty-eight patients (93%) had been in hospital for > 1 week and 10 patients (33%) for > 1 month when they developed endocarditis. Left-sided infection was most frequent; only 3 cases involved the tricuspid valve. Compared with community-acquired infection, patients tended to be older, had a greater incidence of congestive cardiac failure (p = 0.001) or hypotension (p = 0.0008) at presentation and were more likely to have bacteremia after an invasive procedure (83 vs 31%; p < 0.00001). Intravascular devices were the presumed source of bacteremia in 11 cases (37%); the same organism was isolated from both the blood and the suspected source of infection. Staphylococcus aureus was the most frequent causative organism, accounting for 17 episodes (57%), including 4 (13%) due to methicillin-resistant strains. Nosocomial endocarditis had a significantly higher mortality than did community-acquired infection (40 vs 18%; p = 0.02). Eight patients (27%) needed valve replacement. Proper adherence to protocols for management of intravascular devices and appropriate antimicrobial prophylaxis before procedures may have prevented endocarditis in 15 of 30 patients.

Entities:  

Mesh:

Year:  1992        PMID: 1442617     DOI: 10.1016/0002-9149(92)90298-d

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Clinical and bacteriological characteristics of infective endocarditis in the elderly.

Authors:  C Selton-Suty; B Hoen; A Grentzinger; P Houplon; M Maignan; Y Juillière; N Danchin; P Canton; F Cherrier
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

2.  [Description of 8 cases with gonadal dysgenesis syndrome type 46XY].

Authors:  E Deligeoroglou; P Fotaki; D Kokkalis; G Creatsas
Journal:  Akush Ginekol (Sofiia)       Date:  2001

3.  Hospital acquired native valve endocarditis: analysis of 22 cases presenting over 11 years.

Authors:  C C Lamas; S J Eykyn
Journal:  Heart       Date:  1998-05       Impact factor: 5.994

4.  Methicillin-resistant versus methicillin-sensitive Staphylococcus aureus infective endocarditis.

Authors:  E E Hill; W E Peetermans; S Vanderschueren; P Claus; M-C Herregods; P Herijgers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-26       Impact factor: 3.267

5.  Health care-associated native valve endocarditis: importance of non-nosocomial acquisition.

Authors:  Natividad Benito; José M Miró; Elisa de Lazzari; Christopher H Cabell; Ana del Río; Javier Altclas; Patrick Commerford; Francois Delahaye; Stefan Dragulescu; Helen Giamarellou; Gilbert Habib; Adeeba Kamarulzaman; A Sampath Kumar; Francisco M Nacinovich; Fredy Suter; Christophe Tribouilloy; Krishnan Venugopal; Asuncion Moreno; Vance G Fowler
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

6.  Healthcare-associated infective endocarditis: a case series in a referral hospital from 2006 to 2011.

Authors:  Oslan Francischetto; Luciana Almenara Pereira da Silva; Katia Marie Simões e Senna; Marcia Regina Vasques; Giovanna Ferraiuoli Barbosa; Clara Weksler; Rosana Grandelle Ramos; Wilma Felix Golebiovski; Cristiane da Cruz Lamas
Journal:  Arq Bras Cardiol       Date:  2014-08-29       Impact factor: 2.000

Review 7.  Healthcare-Associated Infective Endocarditis-Surgical Perspectives.

Authors:  Tatjana Musci; Herko Grubitzsch
Journal:  J Clin Med       Date:  2022-08-24       Impact factor: 4.964

Review 8.  Infective endocarditis epidemiology over five decades: a systematic review.

Authors:  Leandro Slipczuk; J Nicolas Codolosa; Carlos D Davila; Abel Romero-Corral; Jeong Yun; Gregg S Pressman; Vincent M Figueredo
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.